The balance of children with Duchenne muscular dystrophy who are moving becomes worse as the disease progresses, suggesting that balanced-focused…
Magdalena Kegel
Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Magdalena Kegel
The strength of neck-flexing muscles not only affects torso movements but also the overall daily performance of children with Duchenne…
Researchers suggest a mutation in the INPP5K gene caused a new type of congenital muscular dystrophy. Individuals affected by the unique…
Bone fragility is a serious consequence of long-term corticosteroid treatment — the main option for Duchenne muscular dystrophy (DMD) —…
More Research Needed to Understand Physiological Responses to Assistive Technology, Study Finds
People with Duchenne muscular dystrophy have a lower heart rate variability than healthy people — an abnormality that worsened after completing…
Treating Duchenne and Becker’s muscular dystrophy patients with angiotensin-converting enzyme (ACE) blocking drugs at early disease stages may slow the…
Using a newly engineered tongue-on-a-chip model of Duchenne muscular dystrophy, researchers found one reason that muscle regeneration fails — muscle stem cells react…
Researchers have developed a new gene therapy for muscle wasting conditions, and are now working to bring into clinical use…
Catabasis to Present Data from MoveDMD Trial in Duchenne Patients at PPMD 2016 Annual Conference
Catabasis’ chief medical officer, Dr. Joanne Donovan, will present results from the first phase of the two-part MoveDMD Trial, exploring…
Recent research has revealed a new way of thinking about muscular dystrophy – and potential future drugs that could target laminin signaling…